Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Olanzapine-Induced Weight Gain in Schizophrenia
NCT05669742Phase 3Recruiting
- Sponsor
- Tanta University
- Start
- May 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in metabolic syndrome, sponsored by Tanta University. Started May 2023; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT05669742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669742.